Sight recovery in retinitis pigmentosa?
Researchers from the Institut de la Vision have contributed to a study with scientists from the Friedrich Miescher Institute for Biomedical Research (FMI), Basel, Switzerland, to restore vision in retinitis pigmentosa.
This novel strategy relies on introducing a photosensitive archaebacterial protein (halorhodopsin) into the remaining but non-functional cone photoreceptors. The concept was first demonstrated on a blind mouse and subsequently confirmed in light-insensitive human retinas in vitro. The types of patients who could benefit from this therapy have also been determined.
These findings could lead in the future to the development of a new therapeutic approach for retinitis pigmentosa that is, at present, an incurable condition.
These breaking results were published in the journal Science (source).
For more information, see the material provided by Inserm, click here.
Rare disease day 2017
The Rare Disease Day - held on the last day of February since its first celebration in 2008 - serves to raise and deepen awareness of rare diseases among the general public, public authorities and decision-makers.Read more
Opening of the Hearing Institute - Group leader positions
The Hearing Institute, an auditory neuroscience research institute, will open in April 2018. Various funding opportunities are available. Both senior and junior group leader applications will be considered.Read more
En partenariat avec l'Institut de la Vision, le congrès Vision-Innovation© se déroulera le 10 février 2015 à la Maison de l'UNESCO.